Editing
Renal Transplant
(section)
Jump to navigation
Jump to search
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
== Post-transplant care == * '''The best predictor of immediate graft function following living donor renal transplantation is donor kidney output just prior to nephrectomy.''' * Low-molecular-weight heparin is eliminated by the kidney and must be used cautiously in the setting of unpredictable metabolism to minimize bleeding complications. * In patients with reasonable bladder capacity, the urinary catheter may be removed on postoperative day 3 and the closed suction drain removed later in the day if drain output remains low. * '''The most common early complications of renal transplantation include (6):''' *# '''Infection''' *# '''Bleeding''' *# '''Urinary leak''' *#* '''Leaks manifest in the early post-operative period with decreased urine output from the urinary catheter and increased output from the closed suction drain.''' *#* '''If the leak occurs after the urethral catheter has been removed, the catheter should be replaced immediately.''' *#* '''Many anastomotic leaks will heal with the ureteral stent in place and catheter drainage.''' *#** '''Leaks that do not heal with conservative measures may require placement of a percutaneous nephrostomy tube or open repair''' *# '''Lymphatic leak''' *#* Lymphoceles can originate from the transplant kidney or the lymphatic channels that surround the iliac vessels *#* Incidence of lymphoceles can be reduced by routine placement of a closed suction drain that is removed when the output is < 50 mL/day. *#* '''Many lymphoceles are small and inconsequential, but large lymphoceles may:''' *#** '''Cause pain''' *#** '''Become infected''' *#** '''Compress the allograft, leading to dysfunction''' *#* Lymphoceles are well visualized on ultrasound *#* '''Management''' *#*# '''If intervention required, initially treated with image-guided aspiration''' *#*# '''If this fails, a closed suction drain is inserted''' *#*# '''If this fails, sclerosing agents may be used''' *#*# '''If this fails, creating of a peritoneal window can aid in reabsorption''' *# '''Vascular thrombosis''' *#* '''Transplant renal artery thrombosis''' *#** '''Generally occurs within 3 days of the transplant''' *#** '''Associated with hypercoagulable state or delayed graft function''' *#*** Patients at risk for thrombosis should be given anticoagulation therapy *#** '''Diagnosis and Evaluation''' *#*** '''Sudden cessation of urine output''' *#*** Doppler ultrasound reveals no blood flow to the graft *#** '''Management''' *#*** '''Emergent thrombectomy and antithrombolytics should be attempted, but rarely successful''' *#* '''Transplant renal vein thrombosis''' *#** '''Associated with hypercoagulable state, kinking or stenosis of the vein, acute rejection, and hypotension''' *#** Diagnosis and Evaluation *#*** Doppler ultrasound may reveal a clot in the vein and decreased blood flow to the graft *#** '''Management''' *#*** '''Emergent thrombectomy and antithrombolytics should be attempted, but rarely successful''' *#* '''Reasons for elevated renal arterial resistive index in a transplant kidney (7): ARVOCAD''' *#*# '''Renal Artery stenosis (if measured upstream from the stenosis)''' *#*# '''Transplant Rejection (acute or chronic)''' *#*# '''Renal Vein thrombosis''' *#*# '''Ureteric Obstruction''' *#*# '''Perinephric fluid Collection''' *#*# '''Acute tubular necrosis (ATN)''' *#*# '''Drug toxicity''' *#** '''Resistive Index = (peak systolic velocity - end diastolic velocity) / peak systolic velocity; normal = 0.60-0.70''' *# '''Rejection''' *#* '''Classified by temporal occurrence of graft loss:''' *#** '''Hyperacute (humoral) rejection''' *#*** '''Occurs shortly after the reperfusion of kidney transplants''' *#*** '''MOA: Recipient cytotoxic antibodies and complement react with donor vascular endothelial antigens, leading to a rapid activation of the coagulation cascade and graft thrombosis''' *#*** Rarely seen clinically today because of sensitive crossmatch tests to detect DSA. *#** '''Acute rejection''' *#*** '''Classically occurs ≈5 days after an allogeneic organ transplant without immunosuppression.''' *#*** '''Most common presentation is increasing serum creatinine and decreasing urine output''' *#*** Needle biopsy of the kidney graft is the current standard diagnostic test *#** '''Chronic rejection''' *#*** '''Characterized by a gradual deterioration of kidney function''' *#*** The histologic features of interstitial fibrosis, arteriolar sclerosis, and tubular atrophy rarely improve with augmented immunosuppression, and are in some cases the result of drug toxicity. *#* Allograft nephrectomy *#** Can be a technically challenging procedure and is reserved for few clinical situations. *#** Removal of an allograft that has failed during the first year post-transplant can lower levels of anti-HLA antibodies that may make subsequent transplantation more difficult due to positive cross matches. * '''Immunosuppression''' ** '''Advances in immunosuppressive drugs have improved early graft survival rates, but these improvements have had little impact on late graft loss, largely because of chronic rejection.''' ** '''Mechanisms of Action of Immunosuppressants''' *** '''Glucocorticoids: Reduce transcription of cytokine genes''' *** '''Azathioprine: Inhibits purine synthesis''' *** '''Mycophenolate mofetil: Inhibits purine synthesis''' *** '''Sirolimus: Inhibits cell cycle progression''' *** '''Everolimus: Inhibits cell cycle progression''' *** '''Tacrolimus: Inhibits calcineurin and IL-2 production''' *** '''Cyclosporine: Inhibits calcineurin and IL-2 production''' *** '''Rabbit antithymocyte globulin: Depletes T lymphocytes''' *** '''Rituximab: Depletes B lymphocytes''' *** Alemtuzumab: Depletes T and B lymphocytes *** Bortezomib: Proteasome inhibitor *** '''Basiliximab: Blocks IL-2 receptor''' *** Belatacept: Costimulation blockade *** Eculizumab: Complement inhibitor ** See CW11 Table 47-3 for Common Organ Targets for Toxicities of Immunosuppressant Therapy ** '''Corticosteroids most likely to impair wound healing''' ** '''Prednisone, cyclosporine, and sirolimus all result in hyperlipidemia''' ** '''Commonly used regimens to prevent infections and peptic ulcer disease include TMP/SMX for 3 months for prophylaxis against Pneumocystis pneumonia''' ** '''Prophylaxis against cytomegalovirus disease is possible with ganciclovir, acyclovir, valacyclovir, or cytomegalovirus immune globulin''' ** '''Cyclosporine and tacrolimus are metabolized by the cytochrome P450 system; doses may have to be adjusted with concomitant use medications that also involve the cytochrome P450 system (fluconazole, ketoconazole)''' *** '''P450 Inducers''' '''''B'''ull'''S'''hit '''CRAP GPS''' INDUCES my rage!''§ **** '''B'''arbituates **** '''S'''t. John’s wort **** '''C'''arbamazepine **** '''R'''ifampin **** '''A'''lcohol (chronic) **** '''P'''henytoin **** '''G'''riseofulvin **** '''P'''henobarbital **** '''S'''ulfonylureas *** '''P450 Inhibitors''' '''''VICK'''’'''S''' '''FACE''' '''A'''ll '''O'''ver '''GQ''' STOPS ladies in their tracks.''§ **** '''V'''alproate **** '''I'''soniazid **** '''C'''imetidine **** '''K'''etoconazole **** '''S'''ulfonamides **** '''F'''luconazole **** '''A'''lcohol (acute) **** '''C'''hloramphenicol **** '''E'''rythromycin ''(macrolides EXCEPT azithromycin)'' **** '''A'''miodarone **** '''O'''meprazole **** '''G'''rapefruit juice **** '''Q'''uinidine ** '''Diltiazem and ketoconazole have been used to reduce calcineurin inhibitor dosing and cost while maintaining blood levels and immunosuppressive effect''' ** '''Chronic immunosuppression increases the risk for malignancy''' *** '''Skin cancer is the most common malignancy after solid-organ transplant''' *** '''Malignancies associated with viral infection (4):''' ***# '''Kaposi sarcoma (human herpesvirus 8)''' ***# '''Non-Hodgkin lymphoma (EBV)''' ***# '''Vulvar (human papillomavirus)''' ***# '''Hepatocellular (Hepatitis C) carcinoma''' *** '''The incidence of kidney, penile, and bladder cancers are also increased''' **** '''Recall in HIV, increased risk of kidney, penile, and testis; metabolic syndrome has increased risk of kidney, bladder, and prostate''' *** '''The incidence of prostate cancer is actually decreased in transplant recipients''' *** '''Lymphoma may respond to a reduction in immunosuppression''' * '''Fertility''' ** '''After successful kidney transplantation, levels of FSH, LH, and testosterone usually become normal and spermatogenesis improves'''. ** '''Among male recipients who have fathered children, there has been no increase in congenital abnormalities in the offspring. It is recommended, however, that impregnation be delayed for at least 1 year after transplantation.''' ** '''Successful renal transplantation usually restores fertility in premenopausal women''' * '''Hemorrhagic cystitis in an immunosuppressed patient has been most commonly associated with adenovirus'''
Summary:
Please note that all contributions to UrologySchool.com may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
UrologySchool.com:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
Navigation menu
Personal tools
Not logged in
Talk
Contributions
Create account
Log in
Namespaces
Page
Discussion
English
Views
Read
Edit
Edit source
View history
More
Search
Navigation
Main page
Clinical Tools
Guidelines
Chapters
Landmark Studies
Videos
Contribute
For Patients & Families
MediaWiki
Recent changes
Random page
Help about MediaWiki
Tools
What links here
Related changes
Special pages
Page information